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Somatic mosaicism and common genetic variation
contribute to the risk of very-early-onset
inflammatory bowel disease
Eva Gonçalves Serra et al.#
Very-early-onset inflammatory bowel disease (VEO-IBD) is a heterogeneous phenotype
associated with a spectrum of rare Mendelian disorders. Here, we perform whole-exome-
sequencing and genome-wide genotyping in 145 patients (median age-at-diagnosis of
3.5 years), in whom no Mendelian disorders were clinically suspected. In five patients we
detect a primary immunodeficiency or enteropathy, with clinical consequences (XIAP, CYBA,
SH2D1A, PCSK1). We also present a case study of a VEO-IBD patient with a mosaic de novo,
pathogenic allele in CYBB. The mutation is present in ~70% of phagocytes and sufficient to
result in defective bacterial handling but not life-threatening infections. Finally, we show that
VEO-IBD patients have, on average, higher IBD polygenic risk scores than population controls
(99 patients and 18,780 controls; P < 4 × 10−10), and replicate this finding in an independent
cohort of VEO-IBD cases and controls (117 patients and 2,603 controls; P < 5 × 10−10). This
discovery indicates that a polygenic component operates in VEO-IBD pathogenesis.
https://doi.org/10.1038/s41467-019-14275-y OPEN
#A full list of authors and their affiliations appears at the end of the paper.
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Inflammatory bowel disease (IBD) represents a heterogeneousgroup of disorders characterized by a dysregulated immuneresponse toward commensal gut bacteria leading to chronic
relapsing intestinal inflammation1,2. Crohn’s disease (CD) and
ulcerative colitis (UC), the two common forms of IBD, affect
around 0.5% of individuals of European descent with lower, but
rising, prevalence in other parts of the world3.
Though IBD can occur at any age, the peak age of onset for CD
and UC is between 20–30 years and 30–40 years, respectively4.
About 20% of patients develop IBD before the age of 17 years
(pediatric-onset-IBD) and around 14/100,000 children have an
IBD onset under the age of six (very-early-onset IBD)5. Onset of
IBD before the age of 2 years (infantile-IBD) or even within the
first month of life (neonatal-IBD) is exceptionally rare. Patients
with VEO-IBD present with a higher rate of pancolitis, and
subgroups present with severely fistulising disease, resistance to
conventional immunosuppressive treatments and immune defects
associated with increased lethality6,7.
Several Mendelian disorders present with IBD and IBD-like
intestinal inflammation and have an onset during infancy or
within the first 6 years of life8,9. Biallelic loss-of-function variants
in the IL10 signaling pathway (IL10, IL10RA, and IL10RB) are fully
penetrant for VEO-IBD10,11, while genetic variants underlying
several other Mendelian disorders show an incomplete penetrance
of the IBD phenotype (for simplicity called monogenic IBD). The
majority of these conditions are autosomal recessive or X-linked
inherited primary immunodeficiencies (PIDs). A simple differ-
ential diagnosis based on phenotypic associations is often difficult
and a sequential work-up based on candidate genes is time con-
suming. Whole-exome-sequencing (WES) is increasingly used to
screen for causal mutations and such studies have identified
pathogenic variants in a proportion of VEO-IBD patients, in genes
such as IL10, IL10RA, IL10RB, XIAP, TTC7A, and TTC3712–18.
Identifying the underlying disease-causing variants in VEO-IBD
patients is important because it can directly influence patient
management and inform on the appropriate treatment strategy,
e.g., early haematopoietic stem cell transplantation (HSCT) in
patients with haematopoietic defects caused by IL1010, FOXP319,
or XIAP20 mutations.
Rare monogenic forms of IBD are a stark contrast to the
polygenic nature of pediatric and adult-onset IBD. Genome-wide
association studies (GWAS) have identified more than 240 loci
associated with IBD, the majority of which are driven by common
variants (minor allele frequency (MAF) > 5%) of small effect
(increasing risk by 1.1–1.3 fold), together explaining 13 and 8% of
the variance in disease liability for CD and UC, respectively21–23.
The majority of patients included in these GWAS have adult-
onset disease, and very few (<0.1%) have VEO-IBD. Genome-
wide association studies focusing on pediatric-onset cases24,25
identified risk loci that, at the time, were not associated with
adult-onset disease but all have since been robustly associated in
adult-IBD cohorts26. More recently, three studies focusing on
patients with an age at disease onset greater than 6 years, reported
a weak, but statistically significant, negative relationship between
polygenic risk score and the age at CD and UC diagnoses27–29.
The role of polygenicity in VEO-IBD remains unknown and it is
possible that, while rare monogenic variants underlie disease in a
proportion of VEO-IBD patients, an exceptionally high burden of
common IBD-susceptibility alleles may also contribute to VEO-
IBD risk. Such a hypothesis has not been previously investigated
in VEO-IBD cohorts.
Here, we use WES and genome-wide SNP arrays to better
understand the genetic architecture of VEO-IBD in a multi-center
cohort of 145 patients with a median age-at-diagnosis of 3.5 years
and a severe disease course, indicated by previous surgery or need
for biological therapy. We include patients in whom a Mendelian
disorder is unexpected due to clinical presentation, or were
mutation negative following screening of specific VEO-IBD genes
selected based on patient presentation (e.g., IL10, IL10RB, or
IL10RA defects in patients with IBD onset in the first three
months of life). The cohort is therefore potentially enriched for
cases harboring undiscovered monogenic causes of VEO-IBD,
or alternative causal mechanisms. We investigate the extent to
which mutations in 67 known monogenic IBD genes account for
disease in this selected cohort and search for novel monogenic
causes exome-wide. Moving beyond rare variation, we use
genome-wide SNP data to evaluate the role of common CD and
UC-susceptibility alleles in the pathogenesis of VEO-IBD. By
generating polygenic risk scores (PRS) based on the effect-size
estimates of SNPs significantly associated with adult-onset CD
and UC and replication in independent VEO-IBD and control
cohorts, we investigate whether VEO-IBD children harbor a
higher load of such alleles when compared to a large collection of
adult-onset IBD cases or population controls (see Supplementary
Fig. 1 for an overview of the study workflow).
Results
Cohort sequencing and quality control. A cohort of 145 VEO-
IBD individuals and 4436 population controls were exome
sequenced at a mean coverage of 69× and 53×, respectively.
Following sample and variant-based quality control (see Methods
section), 145 VEO-IBD cases and 3969 controls with equivalent
sequencing-based QC metrics (Supplementary Fig. 2) remained
for analysis, with an average of ~40,000 variants called per exome
and 94% of genes covered at a mean depth of 30× or above
(Supplementary Fig. 3). There were two well defined ancestry-
matched groups within our dataset: 104 cases and 3787 controls
defined as being of European descent and 21 cases and 68 con-
trols defined as South Asian (the remaining samples did not
cluster with a clearly defined ancestry group) (see Methods sec-
tion, Supplementary Fig. 4).
Somatic mosaicism: non-Mendelian inheritance of VEO-IBD.
The initial screening for pathogenic variants in established
monogenic IBD genes identified a nonsense mutation in CYBB
(p.W380X) in a 31-year-old male patient of European descent
with infantile-onset of granulomatous colitis, perianal abscesses
and hidradenitis suppurativa (Fig. 1a, f; Table 1). A detailed
clinical summary of the case is presented in Supplementary
Note 1 and Supplementary Fig. 5. Loss-of-function mutations in
CYBB are known to cause chronic granulomatous disease (CGD).
However, our patient had no history of invasive infections, a
potential fatal hallmark of CGD unless patients are closely
monitored and rapidly treated. We found no carriers of the
mutation in more than ~156,000 whole-exome sequences from
ethnically-diverse population controls (including ExAC30 and
gnomAD30).
CYBB resides on the X-chromosome and thus we were surprised
to notice that only 122 out of 174 sequence reads (~70%) covering
the site of the mutation carried the nonsense allele (A) (the other
reads carried the wild-type allele—G). Investigating the common
genetic variation across the X chromosome, we found no evidence
of Klinefelter Syndrome (47 chromosomes, XXY) or partial X-
chromosomal duplication that could explain this observation. We
confirmed the mutation via Sanger sequencing undertaken in an
independent clinical genetics laboratory. We also Sanger-sequenced
DNA from the patient’s mother and sister and established that
neither are carriers of the nonsense mutation (Fig. 1b), suggesting
that the mutation is a de novo event of hemizygous mosaicism.
Accordingly, 70% of neutrophils lacked CYBB protein expression,
further supporting a hemizygous mosaicism (Fig. 1c). Functional
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validation experiments confirmed the mosaicism, with 70% of
neutrophils and monocytes showing completely absent NADPH-
oxidase activity as seen in CGD patients, and 30% of cells showing a
normal profile (Fig. 1d, see Methods section). This degree of
mosaicism affected bacterial handling capacity since monocyte-
derived macrophages from the patient had ~30% more colonies at
baseline but did not respond to muramyl dipeptide (MDP) in
the gentamicin protection assay (Fig. 1e; see Methods section), a
finding suggestive of a bacterial handling defect31. Our results
suggest that the proportion of cells with complete loss-of-function
of CYBB affects the phenotypic presentation, i.e., 30% wild-type
neutrophils is sufficient to prevent life-threatening infections
but 30% fully-functioning macrophages is insufficient to prevent
intestinal inflammation as a result of ineffective bacterial killing
and inflammatory cytokine production.
To further understand the origin and the developmental time
at which the mutation arose during embryogenesis, we sequenced
DNA from several flow cytometry assay (FACS) sorted immune
cell subsets and used DNA from buccal swabs, containing
epithelial cells, and hair follicles from the patient and compared
those with wild type cells (Fig. 1f, g; see Methods section,
Supplementary Fig. 6). In all immune cell subsets of the patient
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(neutrophils, monocytes, CD4+ T cells, CD19+ B cells, NK cells)
we found the mutation was present in around 70% of cells (range:
63–76%), whereas in buccal swabs it was carried by around 60%
(range: 34–90%) of cells. In order to ensure that the approxi-
mately 70% of phagocytes that do not produce reactive oxygen
species correspond to the mutated ones, we sorted DHR-high
and DHR-low neutrophils from the patient (Fig. 1h, Supplemen-
tary Fig. 6). As expected, the DHR-high cells of the patient were
100% wild type, whereas 98% of the DHR-low cells carried the
pathogenic allele (Fig. 1i). In line with the mutated genotype,
the DHR-low population corresponded to a higher number of
bacterial colonies following Salmonella Typhimurium infection
compared to both DHR-high cells from the patient and control
(Fig. 1j), suggesting a clear genotype association with antimicro-
bial capacity. Our results indicate that both mesodermal
(haematopoietic cells) and ectodermal (cheek epithelia and hair
follicles) derived cells are affected and that the mutation arose
early in embryogenesis, likely between days two and five, and
certainly before day nine, the time at which the mesoderm and
ectoderm separate. This case study provides evidence that non-
classical modes of inheritance, such as somatic mosaicism, can
underlie VEO-IBD.
Primary immunodeficiencies as a cause of VEO-IBD. We
identified four patients with an underlying primary immunode-
ficiency. Among the genes screened (Supplementary Table 2)
there were two hemizygous nonsense alleles in XIAP (p.R222X)
and SH2D1A (p.R75X) in two patients (Table 1) of European and
African descent, respectively, and a homozygous missense change
in CYBA (p.S118N), shared by two South Asian siblings (Table 1).
These variants change well conserved amino acids (GERP scores
= 3.8, 2.7, 4.5, respectively), have high CADD scores (37, 38, 25,
respectively), and there are no recessive carriers of these alleles in
more than 156,000 ethnically-diverse population sequences
(including ExAC and gnomAD), indicating that these mutational
events are exceptionally rare in the population (Table 1). A list of
likely benign variants, or variants of uncertain significance
identified in the 67 screened monogenic IBD genes can be found
in the Supplementary Note 2. The majority of the 67 genes were
sequenced at a depth (mean= 67×) comparable to the rest of the
exome (mean= 69×, Supplementary Fig. 3). In keeping with
previous reports13, two of the genes (NCF1 and IKBKG) had poor
coverage (<10×) following WES, and thus pathogenic variants in
these genes may have been missed.
Mutations in XIAP have been associated with X-linked
lymphoproliferative syndrome 2 (XLP2, MIM: 300635). The
premature stop mutation identified in XIAP (p.R222X) disrupts
the region responsible for the XIAP-RIPK2-NOD2 interaction in
the BIR2 domain as well as the C-terminal part of the enzyme
required for ubiquitin ligase activity. Loss-of-function was
experimentally confirmed by absent TNF response after
muramyl dipeptide stimulation (Fig. 2a).
SH2D1A mutations have been causally implicated in X-linked
lymphoproliferative syndrome 1 (XLP1, MIM: 308240). The
SH2D1A nonsense allele (p.R75X) detected in our patient truncates
the protein in the middle of the SH2 domain, the critical region for
signal transduction32. The truncation in SH2D1A was confirmed
by FACS, showing absent binding of a C-terminal detection
antibody (Fig. 2b). The patient died due to severe EBV infection
and liver failure, a severe phenotype previously described in XLP1
patients33.
Mutations in CYBA, which encodes p22phox, cause chronic
granulomatous disease (CGD, MIM: 233690). The p.S118N variant
observed in both our patients is located within the putative
membrane-spanning domain of the protein, where the majority of
missense pathogenic variants have been found34–36. Functional
impairment was confirmed using the dihydrorhodamine-1,2,3
(DHR) assay using several stimuli (formylpeptide, E. coli and
PMA; Fig. 2c), which showed impaired superoxide production in
neutrophils from both siblings. A similar homozygous mutation in
CYBA (p.S118R) has been described previously in a patient with
CGD37.
Exome-wide screening for recessive loss-of-function variants.
In addition to screening for genetic defects that have previously
been described in patients with IBD-like intestinal inflammation,
we searched exome-wide, for homozygous, or potential com-
pound heterozygous, or hemizygous essential loss-of-function
variants in our VEO-IBD cohort. This analysis revealed a
homozygous nonsense variant in PCSK1 (p.R391X), which was
absent from gnomAD and affected a highly conserved nucleotide
(GERP score of 5.4). PCSK1 (Proprotein Convertase Subtilisin/
Kexin type 1) encodes the proprotein convertase enzyme which
cleaves prohormones and defects in the gene have been linked to
an endocrinopathy syndrome characterized by diarrhea but rarely
intestinal inflammation. The patient harboring the PCSK1 variant
was of Asian ancestry and presented with indeterminate mild
colitis before the age of one when recruited to the study. Inter-
estingly, the initial intestinal inflammation did not progress but
the phenotype changed over time. After recruitment and sub-
mission of the DNA sample for sequencing, the phenotype
evolved towards growth delay, excessive weight gain, and endo-
crine disorders including diabetes and hypothyroidism, hypogo-
nadism, cryptorchism, cortisol deficiency, and chronic lung
disease. Whereas the initial phenotype was uncharacteristic, the
subsequent syndromic findings are fully explained by PCSK1
deficiency. This finding highlights the value of next generation
sequencing as a predictive diagnostic tool, as well as the need to
take phenotype progression into account. No other likely essential
loss-of-function variants were identified in our cohort.
Fig. 1 Analysis of CYBB mosaicism in a male patient. a Pedigree structure for the family of the male patient with the mosaic hemizygous mutation in CYBB
(chrX:37,663,371A/G; p.W380X). b Sanger sequencing of the chrX:37,663,371 CYBB mutation site in the patient and unaffected relatives (sister and
mother). c p91-phox protein expression (the gene product encoded by CYBB) analysed by flow cytometry assay (FACS). Control is a healthy donor. d
Measurement of oxidative burst in neutrophils and monocytes using the dihydrorhodamine-1,2,3 (DHR) assay. Obtained from the patient and a healthy
donor (control). e Defective bacterial handling in monocyte derived macrophages with the CYBB mosaicism. Intracellular survival of Salmonella typhimurium
was quantified using the agar plate technique. Results show three technical replicates. Obtained from the patient and a healthy donor (control). f, g
Quantification of mutant read proportion at chrX:37,663,371 using the IGV browser. PBMCs were sorted into immune cell subsets (Supplementary Figs. 6B,
C) and compared with buccal swabs and hair follicles, as well as with healthy donor immune cells and a HEK293T cell line as technical control. h FACS
sorting strategy for DHR-high and DHR-low populations following DHR staining and PMA stimulation (Supplementary Fig. 6A). i Quantification of mutant
reads at chrX:37,663,371 following sorting based on DHR for control DHR-high, patient DHR-high, and patient DHR-low neutrophils (Supplementary
Fig. 6A). j Gentamicin protection assay on neutrophils for control DHR-high, patient DHR-high, and patient DHR-low populations (Supplementary Fig. 6A).
Briefly, neutrophils were infected at a MOI 1:10 for 45min with Salmonella enterica serovar typhimurium and subsequently treated with gentamicin for 45
min. Neutrophils were then lysed and plated on LB agar plates for CFU counting on the following day. ***p < 0.001, Mann–Whitney U-test.
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Searching for VEO-IBD genes: gene-based analysis. To identify
previously unreported genes involved in VEO-IBD, we searched
exome-wide for genes with a significant difference in the burden
of rare variants in our cases versus a large cohort of exome-
sequenced controls (N= 3855 INTERVAL samples; see Methods
section). This approach has the advantage of allowing variants
across the penetrance spectrum to contribute to the association
test (see Methods section). Nine different exome-wide, gene-based
screens were conducted using different variant inclusion criteria
(for variant severity and minor allele frequency; see Methods for
definitions and the Methods). No individual gene achieved exome-
wide significance (Fisher’s exact test P < 1.7 × 10−6 after correction
for multiple testing) irrespective of the variant inclusion criteria
(Supplementary Fig. 7).
Testing for a rare variant burden in pathways and genesets. We
next searched for a rare variant enrichment across multiple
related genes, such as those that reside in the same biological
pathway (see Methods section and Supplementary Table 3). This
approach offers additional statistical power compared to indivi-
dual gene tests, as a larger number of variants are collapsed across
a larger testing unit. In total we tested 195 different biological
genesets, 186 of which represent the whole set of KEGG pathways
available in the KEGG pathway database. No geneset or pathway
showed a significant burden of rare variants in patients versus
controls (N= 3855 INTERVAL samples) after correction for
multiple testing (PLINK/SEQ burden test statistic P < 3.2 × 10−5,
Supplementary Fig. 8).
No evidence of a rare variant burden in PID loci in VEO-IBD.
A previous WES study of 125 VEO-IBD children and 145 healthy
controls38 reported an over-representation of rare, damaging
variation (AF < 0.1%) in PID-associated genes in VEO-IBD
patients (P < 1 × 10−4). We found no evidence (PLINK/SEQ
burden test statistic P= 0.7) of such an enrichment in our VEO-
IBD cohort when compared against a larger set of control
sequences (N= 3855 INTERVAL samples; Supplementary Fig. 8)
and while controlling for potential confounding factors (such as
ancestry and sequencing depth) between cases and controls (see
Methods section).
A polygenic component operates in VEO-IBD risk. We next
searched for a polygenic component underlying the disease using
our genome-wide genotyping data. We calculated a PRS for each
VEO-IBD COLORS patient of European ancestry (N= 99) by
weighting their risk allele count at each disease-associated SNP
(NCD= 147; NUC= 119) by the estimated effect size of the risk
allele (see Methods section). The CD and UC risk polygenic risk
scores were significantly greater in our VEO-IBD cases compared
to a large cohort of population controls (N= 18,780) (Student’s
t-test P= 3.97 × 10−10 and P= 1.23 × 10−10 for CD and UC,
respectively) (Fig. 3). We did not detect a significant difference
between the risk scores of our VEO-IBD cases and a cohort of
13,896 predominantly adult-onset IBD cases ascertained by the
UK IBD Genetics Consortium (Student’s t-test P= 0.457 and
P= 0.661 for CD and UC, respectively) (Fig. 3). We can conclude
that if there is a difference in mean PRS between VEO-IBD and
adult-onset disease then it must be smaller than that seen between
adult-onset IBD cases and controls (Cohen’s d= 0.85 and 0.64 for
CD and UC, respectively) because our sample sizes would provide
100% power to detect such an effect. However, with our sample
sizes we cannot rule out the possibility of a smaller difference in
mean PRS between VEO-IBD and adult-onset IBD cases (Cohen’s
d= 0.2) because 310 VEO-IBD cases would be required to pro-
vide 80% power to detect such an effect, given our sample size ofT
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adult-onset patients and an α of 0.01 (Supplementary Fig. 9). Our
PRS results were not driven by the few loci known to be asso-
ciated with age-at-diagnosis of IBD (NOD2, HLA, and MST1)27
and similar findings were obtained when restricting the CD
polygenic burden test to VEO-IBD cases defined in the COLORS
cohort as CD or CD plus undeterminable IBD (IBDu), and when
restricting the UC polygenic burden test to VEO-IBD cases
defined as UC or UC plus IBDu (Supplementary Fig. 10).
To validate these results we generated polygenic risk scores
across another cohort of European-descent VEO-IBD cases
(Toronto SickKids VEO-IBD, N= 117) and population controls
(NIDDK, N= 2603) with existing genotype data (see Methods
H
LA
D
R
TNF
Unstimulated MDP
Control
XIAP
p.R222X
98% 105
104
103
102101 103 104 105
0
102101 103 104 105102101 103 104
10210110
0
103 104
10210110
0
103 104
105
102101 103 104 105
–103
0
105
104
103
–103
0
105
104
103
–103
0
105
104
103
–103
0
2%
98% 2% 3%97%
65% 35%
a
b
c
Un
sti
m
ula
te
d
Fo
rm
ylp
ep
tid
e
E.
 co
li
PM
A
1
10
100
1000
10,000
D
H
R
 m
ea
n 
flu
or
es
ce
nc
e 
in
te
ns
ity
Control
CYBA p.S118N
CYBA p.S118N
Control
CYBA p.S118N -1
CYBA p.S118N -2
Unstimulated Formylpeptide
E. coli  PMA
Counts
17%
98%
M1
M1
SAP (SH2D1A)
Control
SH2D1A p.R75X
Unstained
Anti-SAP
Counts
DHR
0
150
0
20
40
60
80
100
104103
M1
RHODAMINE 123
102101100
104103
RHODAMINE 123
102101100
C
ou
nt
s
C
ou
nt
s
C
ou
nt
s
70
50
30
25
20
15
10
5
0
40
30
20
10
60
50
40
30
20
10
0
M1
M1
0
0 0 0 0
00
Fig. 2 Functional validation of pathogenic variants identified in monogenic IBD genes. a Defective MDP response in a patient with hemizygous XIAP p.
R222X. MDP (muramyl dipeptide) induced intracellular TNF response was determined using FACS. b Absent SAP staining (gene product of SH2D1A) as
indicated by C-terminal antibody in a patient with hemizygous SH2D1A p.R75X. Measured with fluorescence-activated cell sorting (FACS). c Defecting ROS
production in neutrophils from patients with homozygous CYBA p.S118N variants. Dihydrorhodamine-1,2,3 (DHR) flow cytometry assay (FACS) was
performed to measure NADPH oxidase activity in response to PMA, E. coli particles and formylpeptide.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-14275-y
6 NATURE COMMUNICATIONS |          (2020) 11:995 | https://doi.org/10.1038/s41467-019-14275-y | www.nature.com/naturecommunications
section). We replicated our discovery of a polygenic component
operative in VEO-IBD (Student’s t-test P= 4.60 × 10−10 and P=
4.32 × 10−12 for CD and UC, respectively, Fig. 3).
We were unable to separately quantify the contribution of
common IBD risk variants to VEO-IBD in the presence of a
Mendelian disease because only one COLORS VEO-IBD indivi-
dual included in the PRS analysis had a Mendelian diagnosis
(the other four patients with Mendelian diagnoses were of non-
European descent and were thus excluded from the polygenic
analysis). Using a cohort of exclusively VEO-IBD patients,
our results demonstrate that a polygenic component operates in
VEO-IBD.
Discussion
Using WES in a selected cohort of VEO-IBD patients in whom no
Mendelian disorders were clinically suspected, we identified five
patients with rare, pathogenic mutations in four PID-associated
genes (XIAP, CYBA, CYBB, and SH2D1A), one of which was a de
novo mosaic variant (p.W380X in CYBB). We assessed the
pathogenicity of the variants according to the stringent ACMG
and AMP criteria39, which requires the variant to be absent or
infrequently observed in large population reference cohorts, be
genetically and phenotypically consistent with previous literature,
and have a measurable effect on protein function.
The discovery of these Mendelian variants had a profound
impact on the treatment of the surviving four patients. For
instance, HSCT was initiated in the patient diagnosed with XIAP
deficiency. This patient experienced multiple gastrointestinal
operations and wound healing problems but has not yet devel-
oped EBV-triggered immunopathology (e.g., hemophagocytic
lymphohistiocytosis). Routine infection screening to detect this
potentially fatal complication that commonly develops in XLP2
patients will now be part of his clinical follow-up. Furthermore,
the two siblings with pathogenic variants in the NADPH oxidase
genes (CYBA) were referred to an immunology clinic and stem
cell transplantation is currently being evaluated. The genetic
diagnosis of SH2D1A deficiency was confirmed by the XLP1-
specific extraintestinal complications of EBV-driven disease and
liver failure. The importance of early genetic screening in VEO-
IBD children to allow assessment before full manifestation of
complications, or need for surgery9,13, was highlighted by the
lethal outcome for the patient with SH2D1A deficiency (XLP1,
p.R75X) while WES was being undertaken in this patient.
The patients with XIAP, SH2D1A, and CYBA defects and the
patient with CYBB mosaicism illustrate the opportunities and
challenges with genetic diagnosis in patients with extreme phe-
notypes of IBD, where rare genetic variants can cause both
immunodeficiency, such as invasive infections, and tissue inflam-
mation. In light of the variable manifestation of the phenotype
(some patients with IBD have not presented with the classical
immunodeficiency phenotypes) the intestinal inflammation in
these patients might either be regarded as a manifestation of the
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immunodeficiency (such as XIAP deficiency, XLP1, or chronic
granulomatous disease) or as a form of monogenic IBD.
Somatic mosaicism in CYBB has previously been reported in
two patients with clinical presentation of chronic granulomatous
disease, including liver and perianal abscesses and lymphadeni-
tis40. Yamada et al. identified the mosaic events following func-
tional tests of neutrophil function warranted by the presentation
of CGD. Our study identified the somatic mutation in CYBB via
whole-exome sequencing and showcases how this approach can
be used to find pathogenic mutations that are not indicated by
the clinical presentation of a patient. The two patients reported
by Yamada et al. only had 0 and 1.6% wild-type PBMCs (but
1.8 and 18.8% wild-type cells from buccal swabs) and were
diagnosed with CGD. Our patient had 30% wild-type PBMCs and
showed no symptoms of CGD, suggesting that having around
~30% functional phagocytes is sufficient to prevent these life-
threatening infections (but >2% is insufficient). This is an
important insight into the potential utility of gene therapy for
treatment of CGD; correcting the genetic sequence in around 30%
of phagocytes could be sufficient to prevent serial life-threatening
infections, but unlikely to reduce the risk of intestinal inflam-
mation. The mosaic patient herein reported adds to an expanding
spectrum of NADPH oxidase deficiencies where the degree of
functional NADPH oxidase defect confers variable penetrance
of intestinal and extraintestinal manifestations such as skin
inflammation36,41,42.
It remains to be seen if the extent to which the polygenic
background influences VEO-IBD susceptibility varies depending
on the monogenic “foreground”. For example, the polygenic
burden of IBD risk alleles may be of little phenotypic con-
sequence in the presence of fully penetrant VEO-IBD mutations
(such as those seen in the IL10 signaling pathway). This model
would match that seen in patients with diabetes, where indivi-
duals with monogenic MODY have lower polygenic risk score
compared to patients with type 1 diabetes43. However, for
patients with a monogenic VEO-IBD diagnosis that demonstrates
incomplete penetrance for VEO-IBD, the polygenic burden of
IBD risk could play a more significant role in defining the phe-
notype. The recent observation that patients with chronic gran-
ulomatous disease (CGD) and intestinal inflammation have a
greater burden of classical IBD risk variants compared to CGD
patients without intestinal inflammation44 supports this general
hypothesis. We show that, at least for individuals with VEO-IBD
and no current genetic Mendelian diagnosis, common genetic
variants associated with susceptibility to Crohn’s disease and
ulcerative colitis do play a role in disease. It has recently been
shown that there is a weak, but statistically significant, inverse
correlation between age of IBD onset and burden of IBD asso-
ciated risk alleles27–29. We found no evidence to support the
hypothesis that VEO-IBD is due to an increased burden of
common IBD susceptibility alleles relative to adult-onset disease,
but larger sample sizes than ours are required to powerfully
search for small differences in PRS. This model applies in familial
hypercholesterolemia, a dominantly-inherited disorder where
individuals with very high LDL-cholesterol and no known
monogenic cause of disease have a particularly high burden of
common cholesterol-increasing alleles45. The recent identification
of common genetic variants that are associated with Crohn’s
disease prognosis but not susceptibility also suggests that the
search for disease age-at-onset loci should be performed genome-
wide and not just restricted to known IBD susceptibility loci27.
In summary, our data show that primary immunodeficiencies
caused by rare genetic variants can be found in some VEO-IBD
patients even if no Mendelian disease was clinically suspected,
suggesting that genetic screening is relevant across this entire
patient group. We implicate cellular mosaicism with Mendelian
disorder-associated variants as a possible mechanism underlying
VEO-IBD, as highlighted by our case study. Finally, we show that
whatever factors are driving an early age at disease onset in
individuals without a conclusive Mendelian diagnosis, in the
majority of patients they do so on a polygenic background similar
to classical IBD.
Methods
Patient and controls samples. The study was approved by the North Staffordshire
Research Ethics Committee (REC: 09/H1204/30; subproject COLORS in IBD) and
local ethics committees at the study sites. All patients, or their parents, gave written
informed consent before enrollment. The somatic mosaic patient consented to open
access publication of a detailed case report including genetic, clinical, laboratory
data as well as endoscopic and histological images. The cohort consists of 146 VEO-
IBD cases (singletons) without a previous genetic diagnosis, recruited as part of the
COLORS IN IBD project (COLitis of early Onset Rare disorderS in IBD). Samples
were referred from participating centers in the United Kingdom, Switzerland,
Poland and Germany. All patients had a confirmed diagnosis of IBD by standard
methods, including endoscopic, radiologic, laboratory, and clinical evaluation
(ESPGHAN guidelines46). Phenotypic status was based on the Paris Classification47.
Patients were selected according to age-at-diagnosis (<7 years, age of symptom
onset <6 years) and the severity of the IBD phenotype, as indicated by need for
surgery and/or therapy progression to biologics or immunomodulators. When a
clinical diagnosis of a known Mendelian disease was suspected (e.g., IL10, IL10RB,
or IL10RA defects in patients with IBD onset in the first three months of life),
candidate genes were pre-screened by a clinical genetics laboratory. If a genetic
diagnosis was established, the individual was excluded from our study in an attempt
to enrich the cohort with cases harboring undiscovered monogenic causes of VEO-
IBD. Detailed demographic and phenotypic characteristics of the VEO-IBD cohort
are provided in Supplementary Table 1. Whole-exome sequence data from 4436
healthy individuals from the INTERVAL Study (www.intervalstudy.org.uk) were
ascertained for use as controls in exome-based analyses48.
Exome-sequencing of cases and controls. VEO-IBD cases and INTERVAL
controls were sequenced at the Wellcome Trust Sanger Institute (WTSI). Genomic
DNA (1–3 μg) was sheared to 100–400 bp using a Covaris E210 or LE220 (Covaris,
Woburn, Massachusetts, USA). Sheared DNA was subjected to Illumina paired-end
DNA library preparation and enriched for targeted sequencing using the Sur-
eSelectXT Human All Exon kit (Agilent Technologies, Santa Clara, CA, USA;
Human All Exon 50Mb—ELID S04380110) according to the manufacturer’s
recommendations (Agilent Technologies, Santa Clara, CA, USA; SureSelectXT
Automated Target Enrichment for Illumina Paired-End Multiplexed Sequencing).
Enriched libraries were sequenced (eight samples over two lanes) using the HiSeq
2000 platform (Illumina) with paired-end 75 base reads, according to the manu-
facturer’s protocol. The Burrows-Wheeler Aligner49 was used for alignment to the
human reference genome build UCSC hg19/GRCh37 (1000Genomes_hs37d5).
Variants were first called on a per sample basis using GATK Haplotype Caller
(version 3.4) and then joint-called across all cases and controls using GATK
CombineVCFs and GenotypeVCFs using default settings50.
Sample QC. Cross-sample contamination was evaluated using VerifyBAMID
(version 1.1.0). No case samples showed evidence of contamination, however 113
controls had a FREEMIX fraction > 3% and were thus excluded from the study.
Samples with a mean genotype quality (GQ) < 85.4 (representing 3 s.d. from the
mean), a depth < 40, a missing genotype rate > 0.2%, or controls with a close
familial relationship (Pihat > 0.125) were removed from further analysis. A total of
468 poor quality samples (one case and 467 controls) were excluded from sub-
sequent analyses.
Ancestry analysis. Cases and controls were assigned to ancestry-matched groups
based on principal components inferred from the 2504 individuals in the 1000
Genomes Project (1KG) phase 3 data51. Overall, 104 cases and 3787 controls were
defined as Europeans, and 21 cases and 68 controls as South Asians. The remaining
20 cases and 115 controls did not cluster with a clearly defined ancestral group. In
total, 145 of 146 cases and 3969 of 4436 controls remained after QC (Supple-
mentary Fig. 4).
Variant QC. Individual variants were evaluated using Variant Quality Score
Recalibrator (VQSR) using the recommended training sets50 and a 99.9% sensi-
tivity tranche. Individual genotypes with GQ < 20 or depth < 8 were set to miss-
ing52. Variants with more than 10% missing genotypes in either cases or controls
were also removed. In total, 1,267,058 variants passed QC.
Variant annotation. The exome data was annotated using several resources:
dbSNP v137 rsIDs and allele frequencies (AFs) from 1KG phase 1 (N= 2818)53,
NHLBI GO Exome Sequencing Project 6500I (ESP, N= 6500)54, the UK10K low-
coverage study (UK10K_WGS, N= 3781), UK10K WES samples (UK10K_WES,
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N= 4975)55, the Exome Aggregation Consortium r0.3 (ExAC, N= 60,706)30 and
the Genome Aggregation Database (gnomAD, N= 141,356)30. Functional anno-
tations were added using the Ensembl Variant Effect Predictor (VEP version 75)56
according to Gencode v19 coding transcripts, using the most severe consequence
on the gene. Deleteriousness scores for missense variants were inferred using the
SIFT57 and PolyPhen-258 algorithms. Conserved amino acids were identified using
GERP59.
Rare variants were defined as those that were absent or had AFs < 1% in
reference datasets. We defined two broad categories of variants, based on predicted
functional impact at the protein level: (1) Functional: transcript ablation, stop
gained/lost, stop retained, splice donor/acceptor/region, frameshift, inframe
insertion/deletion, initiator codon, and missense variants and (2) Disruptive:
nonsense, frameshift and splice acceptor/donor variants or missense variants with a
PolyPhen-2 and SIFT pathogenicity predictions of “possibly damaging/deleterious”
(or greater) and a GERP score > 2.
Screening of known IBD-associated Mendelian disorder genes. A list of 67
genes known to be associated with Mendelian disorders with IBD-like inflamma-
tory phenotypes was ascertained from the literature8,9,60. The mode of inheritance
and associated disorders for these genes are listed in Supplementary Table 2. We
screened these genes for rare disruptive variants consistent with the established
mode of inheritance. For variants on the X chromosome, we also assessed possible
instances of non-classical inheritance, such as non-random X-inactivation events in
females, or somatic mosaicism in males. To assess the pathogenicity of the variants
identified and to adhere to current best practices39,61, we checked that the patient’s
phenotype data matched that reported for the Mendelian disorder, and performed
functional validation assays to measure the biological impact of the identified
mutations. Genetic variants were classified according to the five-tier terminology
system recommended by the American College of Medical Genetics and Genomics
(ACMG) and the Association for Molecular Pathology (AMP)39. All pathogenic
and likely pathogenic variants were validated by an independent clinical genetics
laboratory using Sanger Sequencing. We investigated whether any of the identified
rare variants were already described as causative for the respective Mendelian
disorder based on searches of the literature and the Human Gene Mutation
Database (HGMD).
For gene-wide sequencing performance, sequencing coverage per gene was
calculated by extracting the read depth at each nucleotide (within exonic sequences
of each of the 67 genes) on a per-sample level using BAM files and SAMtools
mpileup. The read depth was then averaged per-coordinate across samples to
produce an average capture per position, as well as a mean and median coverage
per gene. The exonic regions of genes were defined by Ensembl v75
(Supplementary Fig. 3).
To identify novel VEO-IBD associated genes, we conducted a gene-based
case–control analysis testing for an enrichment of rare variants in VEO-IBD cases
versus controls using the Fisher’s exact test implemented in PLINK/SEQ (https://
atgu.mgh.harvard.edu/plinkseq). We tested four different AF thresholds (<1, <0.5,
<0.1% and unique variants) across our two different functional categories
(functional and disruptive variants), plus one test for functional <1% homozygous
variants only (to avoid diluting a genuine recessive signal). The significance of each
gene was empirically assessed by permuting case–control labels 20,000 times, with
testing conducted for each permutation as outlined above. These tests were
performed within the two population subgroups (Europeans and South Asians)
and the results from both subgroups were meta-analysed using the PLINK/SEQ
SMP method62, to control for population stratification.
We tested for an enrichment of rare variants in nine biologically relevant
genesets (Supplementary Table 3) and across all available KEGG pathways (N=
186) (http://software.broadinstitute.org/gsea/msigdb) using the SMP algorithm62.
We did this across each of the AF thresholds and functional categories defined
above. The BURDEN test was applied across each gene in our case–control
population subgroups and its 20,000 permuted datasets. The test-statistic of a given
geneset was then defined as the sum of the single-gene statistics for all genes
contained in that geneset. To better control for potential baseline differences (such
as depth) between cases and controls, the enrichment of each geneset was expressed
relative to the enrichment observed exome-wide (when considering all genes
harboring at least one rare variant in samples).
Genome-wide genotyping of VEO-IBD cases. VEO-IBD cases were genotyped
using the Illumina Infinium Core Exome v12.1 chip. Poorly genotyped SNPs,
defined as sites with a missing genotype rate >5%63, were removed. Five European-
descent VEO-IBD samples with autosomal heterozygosity rates >3 s.d. from the
mean were excluded. Data were phased using SHAPEIT v264 and imputation
performed using IMPUTE v265 with 5010 haplotypes from the 1KG phase 3 data51.
Genotypes with an INFO score below 0.9 were excluded from the dataset.
Polygenic risk score calculation. We assessed the contribution of IBD loci
associated with adult-onset IBD to VEO-IBD21,22. This analysis made use of the
genome-wide genotype and imputation data, rather than our exome-sequences,
because the vast majority of IBD associations identified via GWAS are located in
intergenic or intragenic regions and are best tagged by non-coding variants. To
enable the VEO-IBD risk scores to be compared with those from non VEO-IBD
cases and controls, we obtained high quality genome-wide genotype data for a large
European-descent cohort of 13,896 IBD cases from the UK IBD Genetics
Consortium22,23 and 18,843 population controls drawn from The 1958 British
Birth Cohort and the UK Blood Service (both genotyped as part of the Wellcome
Trust Case Control Consortium project) and the UK Household Longitudinal
Study. To minimize population stratification we restricted our risk score analysis to
European-descent VEO-IBD cases of high genotype quality (N= 99). The SNP set
for the risk score calculation was generated by selecting the most associated SNP
showing at least suggestive evidence of association (P < 1 × 10−5) with CD or UC in
the European cohort of the largest IBD GWAS meta-analysis at the time of the
analysis21. This resulted in 174 and 146 alleles associated with CD or UC,
respectively. Proxy markers with an r2 > 0.9 were selected substitute SNPs that were
absent from the VEO-IBD and/or UKIBDGC genotype data. Post QC, a total of
147 CD and 119 UC-associated alleles were available in both the VEO-IBD and the
UKIBDGC genotype data. UKIBDGC samples with outlying missingness rates,
across all the backbone SNPs used for the risk analysis, were excluded from the
analysis. This results in a total of 7578 CD cases (mean age at disease diagnosis=
27 years) and 6318 UC cases (mean age at disease diagnosis of 36 years) available
for the analysis. The additive multi-SNP polygenic risk score for each sample was
calculated using PLINK2 (www.cog-genomics.org/plink/2.0/), by summing the log
of the odds ratio (OR) for each risk allele j carried across all disease loci (m):
log riskð Þ ¼
Xm
j¼1
logðORjÞ ´ xij;
where xij is the number of risk alleles at SNPj carried by individuali, and ORj is the
allelic odds ratio at SNPi as estimated by Liu et al. or De Lange et al.21,22 Risk scores
were compared between groups using the Student’s t-test and assuming a sig-
nificance threshold of P < 8 × 10−3, which accounts for the six pairwise compar-
isons between VEO-IBD cases, IBD cases and controls, in CD and UC. Power
estimations were performed using the R package pwr. Cohen’s d was estimated
using the R package lsr.
Validation of polygenic risk scores in VEO-IBD. To validate the risk scores
obtained in our VEO-IBD COLORS cohort, we used a cohort of 117 VEO-IBD
patients from the SickKids Toronto IBD cohort, and a cohort of population con-
trols from the NIDDK IBD Genetics Consortium. The SickKids Toronto IBD
cohort comprises 956 samples genotyped using the Immunochip, an Illumina
Infinium microarray comprising 196,524 SNPs and small indel markers selected
based on results from genome-wide association studies of 12 different immune-
mediated diseases. The NIDDK IBD Genetics Consortium control cohorts included
1008 and 2463 controls genotyped with Illumina’s Infinium Global Screening
Array, which includes a set of fixed markers (N= 665k) as well as a set of addi-
tional custom markers (NIDDK-Broad, N= 700,078; NIDDK-Feinstein, N=
710,468). Quality control, genome-wide SNP imputation and the construction of
the polygenic risk scores in the SickKids Toronto IBD and NIDDK cohorts was
performed using the same pipeline applied to the VEO-IBD COLORS cohort.
Briefly, we excluded samples and common variants with missingness >5%. Low
frequency variants (MAF < 1%) with missingness >2%, and variants deviated from
Hardy-Weinberg equilibrium (P < 10−8, Fisher’s exact test) were also removed. We
also excluded samples with autosomal heterozygosity rates > 3 s.d. from the mean,
duplicate samples or close relatives (pi_hat ≥ 0.125), and non European-descent
samples identified through PCA. After SNP and sample quality control, the
replication cohort consisted of 671 European ancestry cases with genotype data for
147,575 autosomal SNPs, plus 849 NIDDK-Broad and 1754 NIDDK-Feinstein
controls with genotype data for 521,576 and 550,555 autosomal SNPs, respectively.
Genotypes were pre-phased with SHAPEIT2 v264 and imputed with IMPUTE265
using the 1KG phase 3 as a reference panel51. Imputed data for rs564349 was not
available in 1KG Phase 3, so was generated using 1KG Phase 153 as a reference
panel for the NIDDK control cohorts. The subset of 117 VEO-IBD samples were
selected for inclusion in our replication study (detailed characteristics of this VEO
subset are provided in Supplementary Table 4). Polygenic risk scores were calcu-
lated using the same set of 147 CD and 119 UC associated SNPs as for the
COLORS VEO-IBD and UKIBDGC discovery cohorts.
DHR FACS to measure NADPH activity. The neutrophil oxidative burst assay to
detect reactive oxygen species by DHR FACS assay was performed using standard
techniques66. Briefly, EDTA blood was incubated with DHR-123 (Life Technolo-
gies, D23806) at 2.5 μg/mL for 15 min at 37 °C followed by PMA (Sigma, P1585) at
100 ng/mL stimulation and FACS staining. DHR response was measured in FSC/
SCC gated neutrophils. The stimulation index refers to the ratio of the mean
fluorescence of the stimulated cells to the mean fluorescence observed in the
unstimulated cells in the DHR assay.
FACS of cells with differential NADPH oxidase activity. For cell sorting, DHR
FACS was performed as described above with a lower PMA stimulation (50 ng/mL,
ThermoFisher) to ensure viability for neutrophils in the subsequent gentamicin
protection assay. Neutrophils were gated based on cell size and sorted for DHR
fluorescence. DHR-high cells were sorted from a healthy control, the neutrophils
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from the patient were sorted into a DHR-low and DHR-high population (BD FACS
Aria III). Sorting performed with an 85 micron nozzle.
MiSeq analysis of flow-sorted neutrophils. The proportion of the flow-sorted
cells carrying the mutation was determined by NGS in a targeted 3-PCR approach.
The primers were designed using the Eurofins Genomics PCR Primer Design Tool
or provided by Illumina Inc. and synthesized by Sigma-Aldrich (Suffolk, United
Kingdom). The PlatinumTaq DNA Polymerase High Fidelity Kit (11304-011,
Invitrogen) was used according to the instructions of the manufacturer, with a final
reaction volume of 10 µL, final primer concentration of 0.2 µM, 25 cycles and an
annealing temperature (Ta) of 60 °C, unless otherwise stated. A successful PCR was
confirmed after each reaction by detecting an appropriately sized band on a 2%
agarose gel. The first primer pair (F:ACTCACCCTTTCAAAACCATC, R:
ACTTGGCCTTGACCCTTAC) amplified a 513 bp fragment surrounding the
variant of interest from 6 ng of genomic DNA. The second primer pair (F:
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCACCCTTTTACACTGAC
ATCC, R:TCGGCATTCCTGCTGAACCGCTCTTCCGATCTAGTGCCATTTT
TCCTGAACTC) used 0.5 µL of the resulting amplicon to amplify a 258 bp frag-
ment composed of 192 bp of the template surrounded by the Illumina Adapter 5′
and 3′ overhangs. This amplicon was diluted 1:100 in nuclease-free water, and
0.5 µL of the dilution was used as a template to append indexes in a third PCR
(Ta= 70°). All samples shared a forward primer (AATGATACGGCGACCAC
CGAGATCTACACTATAGCCTACACTCTTTCCCTACACGACGCTCTTCCG
ATCT) with the 8 bp index TATAGCCT, whilst each had a different reverse primer
composed of a common core (CAAGCAGAAGACGGCATACGAGAT--------GA
GATCGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATC) and a unique 8
bp index (--------: AACGTGAT, AAACATCG, ATGCCTAA, AGTGGTCA,
ACCACTGT, ACATTGGC, CAGATCTG). The indexed samples were pooled
together (2 µL each) and purified using AMPureXP beads (A63880, Beckman
Colter) at a ratio of 0.6×. The purified library was quantified with the KAPA
Library Quant Kit (Illumina) (KK4824, KAPA Biosystems) on a StepOnePlus Real-
Time PCR System, and the size of the amplicon confirmed with a DNA 1000 Kit
(5067-1504, Agilent Technologies) on an Agilent 2100 Bioanalyzer System, both
according to the instructions of their respective manufacturer. The library was
spiked with 30% of a PhiX library provided in the MiSeq v2 Reagent Kit 300 Cycle
PE Kit (15033624, Illumina) and sequenced on a MiSeq platform using 150 paired
end reads. The resulting reads were filtered against low quality reads, aligned to the
reference genome hg19 and the proportions of each allele quantified using the
DNA Amplicon (Illumina, Inc) workflow provided on the BaseSpace platform.
Mosaicism analysis. The Isohelix swab pack (SK-1S, Isohelix) was used to collect
buccal swabs from the patient. DNA was extracted using the QIAmp DNA mini kit
(QIAGEN) according to the manufacturer’s protocol. For hair follicle analysis,
material was treated with 20 μL 1M DTT, 300 μL buffer ATL and 20 μL proteinase
K for 1 h at 56 °C. We then proceeded with the DNeasy blood and tissue kit
(Qiagen). PBMCs were isolated from whole blood using Lymphoprep (Axis-
Shieldand) and Ficoll gradient centrifugation. Cells were re-suspended in RPMI-
1640 (Sigma), the granulocyte layer extracted67, erythrocytes lysed with water and
the white granulocyte pellet was collected. Cells were stained using CD56 (BV510,
clone HCD56, Biolegend, catalog number 318340), CD14 (BV650, clone M5E2,
Biolegend, catalog number 563420), CD19 (BV711, clone SJ25C1, BD Horizon,
catalog number 563038), CD3 (PE/Dazzle 594, clone UCHT1, Biolegend, catalog
number 300450), CD4 (BV605, clone OKT4, Biolegend, catalog number 317438),
CD8 (AF700, clone SK1, Biolegend, catalog number 344724) and DAPI (1:8000
dilution, Merck, catalog number D9542). To stain the granulocytes, CD16 (PE-Cy7,
clone 3G8, Biolegend, catalog number 302016), Siglec-8 (PE, clone 7C9, Biolegend,
catalog number 347104) and DAPI (1:8000 dilution, Merck, catalog number
D9542) were used. All antibodies were used at a 1:100 dilution unless otherwise
stated. Cells were washed and filtered prior to sorting on BD FACS Aria III.
As a control for our sequencing analysis, we extracted DNA from the HEK293T
(ATCC-CRL-11268) cells using the DNeasy blood & tissue kit (Qiagen).
Primers for PCR were designed using NCBI Primer Blast for regions flanking
the locus of interest and synthesized by Life Technologies. Fifty nanogram DNA
amplified using the Phusion High Fidelity DNA Polymerase kit and (#M0530L,
New England Biolabs) 5× Phusion HF buffer (New England Biolabs) with a final
concentration of 0.5 μM of forward (5′ AAGTGCCCAAAGGTGTCCAA 3′) and
reverse (5′ AGCTTCAGATTGGTGGCGTT 3′) primers (CYBB-F and CYBB-R
primers, respectively) resulting in a 230 bp fragment in each reaction. A 230 bp
fragment containing the mutation site was separated using agarose gel
electrophoresis and Sanger sequenced. To quantify the proportion of cells carrying
the mutation, we used targeted next generation sequencing of 3 replicates per cell
type. Briefly, 5 ng of DNA template was amplified using Phusion® High-Fidelity
PCR Master Mix in the presence of EvaGreen Dye (Biotium, USA) followed by
thermal cycling in a real-time thermal cycler using a standard PCR protocol.
Presence of correct PCR products was confirmed using melting curves. The PCR
products were then directly used for five additional cycles of PCR using Phusion
DNA polymerase and indexing oligos. Different indices were used for each
replicate of all samples. All products were then pooled and purified using AMPure
XP beads (Beckman Colter, USA) at a 0.8× bead ratio. The library was sequenced
on an Illumina MiSeq platform. Reads were mapped to the hg19 human reference
genome using Bowtie268 and visualized using IGV 2.3 (http://software.
broadinstitute.org/software/igv/). Variant calling across the region
(chrX:37639270-37672714) was carried out using Platypus69.
Gentamicin protection assay. The neutrophil gentamicin protection assay was
adapted from Riffelmacher et al, 201770. Briefly, neutrophils were sorted into
RPMI1640 (Sigma) and 10% FCS (Sigma). Monocyte derived macrophages were
generated from PBMCs as previously described31. Forty-thousand neutrophils or
macrophages were infected in a 96-well round-bottom plate or flat-bottom plate,
respectively, at a MOI 1:10 using Salmonella enterica serovar Typhimurium for
45 min or 1 h, respectively. Cells were treated with 100 μg/mL gentamicin (Sigma)
for a further 45 min for neutrophils, or 2 h for macrophages. Cells were then lysed
in 1%-Triton X-100 (Sigma) in H2O. Lysates were plated on LB agar plates using
the track method and CFU were quantified the following day.
MDP induced intracellular TNF response. Quantification of intracellular TNF in
monocytes was performed as previously described31,71. Briefly, freshly isolated
PBMC were rested overnight in RPMI 10% FCS. Unstimulated cells were compared
with MDP and LPS (lipopolysaccharide) stimulated cells. Intracellular TNF
(MAb11, eBioscience) was detected in CD14+HLADR+monocytes (CD14 (M5E2)
and HLA-DR (L243), both BioLegend). Viable cells were detected based on live-
dead staining (Fixable Viability Dye, eBioscience).
SAP expression. FACS was used to quantify SAP protein expression encoded by
SH2D1A as previously described72. In brief, blood cells were incubated with mouse
anti-human CD3 (BD Bioscience, Clone SK7, cat 345767), mouse anti-human
CD8-PerCP (BD Bioscience, Clone SK1, cat 345774), and mouse anti-human
CD56-PE (BD Bioscience, Clone MY31, cat 345810). Samples were then fixed,
washed, an permeabilized. The anti-SAP antibody (Stratech Scientific Biosciences;
clone 1C9, cat H00004068-MO1) or isotype control antibody (IgG1 isotype control;
BD Biosciences 349040). Samples were again washed and stained with anti-mouse
IgG1-FITC (Dako; F0479) before FACS analysis.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Sequencing and genotyping data that supports this study have been deposited to the
European Genome-phenome Archive (EGA) under the accession code
EGAS00001000513 and EGAS00001000924, respectively. All other data are contained in
the paper and its supplementary information or available upon request.
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